Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
9 hedge funds and large institutions have $38.8K invested in Eagle Pharmaceuticals, Inc. in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 55 closing their positions.
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
86% less funds holding
Funds holding: 65 → 9 (-56)
100% less capital invested
Capital invested by funds: $31.9M → $38.8K (-$31.9M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 55
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
+$27.9K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$3.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$8.79M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$4.52M |
| 3 |
Citigroup
New York
|
-$3.73M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.16M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.4M |
EGRX Hedge Fund Activity: Q4 2024 in Review
9 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2024, worth a combined $38.8K — down 100% from $31.9M a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of EGRX and 0 opened new positions — a net loss of 55 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Simplex Trading, adding an estimated $27.9K. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $8.79M sold.
- 9 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2024, down from 65 in Q3 2024.
- Funds reported $38.8K of Eagle Pharmaceuticals, Inc. stock for Q4 2024, down 100% quarter-over-quarter.
- 0 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2024 and 55 closed out, a net change of -55 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2024 was Simplex Trading, an estimated $27.9K added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q4 2024 was Nantahala Capital Management, an estimated $8.79M sold.
Based on aggregated 13F filings for Q4 2024.